Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Stage IA Lung Adenocarcinoma
NCT07235280Phase 1Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dapagliflozin in lung adenocarcinoma, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Incidence of adverse events. Started Dec 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT07235280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235280.